Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Jan;83(1):77-85.
doi: 10.1038/sj.clpt.6100230. Epub 2007 May 9.

Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo

I E Templeton  1 , K E Thummel, E D Kharasch, K L Kunze, C Hoffer, W L Nelson, N Isoherranen
Affiliations
Clinical Trial

Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo

I E Templeton et al. Clin Pharmacol Ther. 2008 Jan.

Abstract

Itraconazole (ITZ) is metabolized in vitro to three inhibitory metabolites: hydroxy-itraconazole (OH-ITZ), keto-itraconazole (keto-ITZ), and N-desalkyl-itraconazole (ND-ITZ). The goal of this study was to determine the contribution of these metabolites to drug-drug interactions caused by ITZ. Six healthy volunteers received 100 mg ITZ orally for 7 days, and pharmacokinetic analysis was conducted at days 1 and 7 of the study. The extent of CYP3A4 inhibition by ITZ and its metabolites was predicted using this data. ITZ, OH-ITZ, keto-ITZ, and ND-ITZ were detected in plasma samples of all volunteers. A 3.9-fold decrease in the hepatic intrinsic clearance of a CYP3A4 substrate was predicted using the average unbound steady-state concentrations (C(ss,ave,u)) and liver microsomal inhibition constants for ITZ, OH-ITZ, keto-ITZ, and ND-ITZ. Accounting for circulating metabolites of ITZ significantly improved the in vitro to in vivo extrapolation of CYP3A4 inhibition compared to a consideration of ITZ exposure alone.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structures of itraconazole (ITZ) and its metabolites hydroxy-itraconazole (OH-ITZ), keto-itraconazole (keto-ITZ) and N-desalkyl-itraconazole (ND-ITZ). * indicates a chiral center.
Figure 2
Figure 2
Selected ion chromatograms from a representative subject plasma showing the detection of itraconazole (ITZ), hydroxy-ITZ (OH-ITZ), keto-ITZ and N-desalkyl-ITZ (ND-ITZ) in vivo after administration of 100 mg itraconazole in oral solution.
Figure 3
Figure 3
Mean plasma concentration (± SD) versus time curves for itraconazole (a), hydroxy-itraconazole (OH-ITZ) (b), keto-itraconazole (keto-ITZ) (c) and N-desalkyl-itraconazole (ND-ITZ) (d) on day 1 (solid boxes) and day 7 (open circles) of the study in the six volunteers. The symbols are the mean values of the six subjects and the bars show standard deviation. For keto-ITZ only two subjects had quantifiable plasma concentrations at 24 hours after the first dose and for ND-ITZ only one subject had quantifiable plasma concentrations at 0.5 hours after first ITZ dose. For calculation of the mean concentration other plasma concentrations were considered to be zero.
Figure 4
Figure 4
The predicted time-course of CYP3A4 inhibition by ITZ and its metabolites on study day 1 (A) and day 7 (B) and the relative contribution of each inhibitory species to the overall CYP3A4 inhibition on study day 1 (C) and day 7 (D). The insets in A and B depict the time course of the total predicted fold decrease in the intrinsic clearance of a CYP3A4 substrate when ITZ and its metabolites are all used for prediction. Closed diamonds show ITZ, open diamonds OH-ITZ, open boxes keto-ITZ and crosses ND-ITZ.
See this image and copyright information in PMC

References

    1. Haria M, Bryson HM, Goa KL. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs. 1996;51:585–620. - PubMed
    1. Poirier JM, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet. 1998;35:461–473. - PubMed
    1. Barone JA, et al. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother. 1998;42:1862–1865. - PMC - PubMed
    1. Hardin TC, et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother. 1988;32:1310–1313. - PMC - PubMed
    1. Schäfer-Körting M. Pharmacokinetic optimisation of oral antifungal therapy. Clin Pharmacokinet. 1993;25:329–341. - PubMed

Publication types

MeSH terms